You are here

  • Home
  • Archive
  • Volume 18, Issue 2
  • Delayed acyclovir therapy in neonates with herpes simplex virus infection is associated with an increased odds of death compared with early therapy

Article Text

Article menu
Download PDFPDF
Online articles
Cohort study
Delayed acyclovir therapy in neonates with herpes simplex virus infection is associated with an increased odds of death compared with early therapy
  1. Sarah S Long
  1. Section of Infectious Diseases, St Christopher's Hospital for Children, Philadelphia, Pennsylvania, USA
  1. Correspondence to : Sarah S Long
    Section of Infectious Diseases, St Christopher's Hospital for Children, 3601 A Street, Philadelphia, PA 19134, USA; sarah.long{at}drexelmed.edu
View Full Text

http://dx.doi.org/10.1136/eb-2012-100674

Statistics from Altmetric.com

    Commentary on: Shah SS, Aronson PL, Mohamad Z, et al. Delayed acyclovir therapy and death among neonates with herpes simplex virus infection. Pediatrics 2011;128:1153–60.OpenUrlAbstract/FREE Full Text

    Context

    High-dose acyclovir therapy substantially reduces death and improves neurological outcome from neonatal herpes simplex virus (HSV) infection.1 The effect of time of initiation of therapy on outcomes is not known precisely. Shah and colleagues sought to determine whether delayed acyclovir therapy after hospitalisation was associated with death among neonates with HSV infection.

    Methods

    In this retrospective, multicentre observational study, data were obtained from the Paediatric Health Information System (PHIS), a US national database containing resource-utilisation data during hospitalisation in 41 freestanding, tertiary care children's hospitals from 2003 through 2009. Infants ≤28 days of age with a discharge diagnosis of HSV infection were studied. The primary exposure of interest was early acyclovir administration (given …

    View Full Text

    Footnotes

    • Competing interests None.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions